Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias

Leukemia Research
Elena SerranoJosep F Nomdedéu

Abstract

Acute myeloid leukemia (AML) is a heterogeneous group of disorders characterized by an abnormal proliferation of the myeloid precursors and a maturation block. The most common chromosomal lesions in AML are the t(8;21) and inv(16). To better understand the leukemogenic mechanism of these fusion proteins, we performed gene expression studies in samples from (8;21), AML1 mutated and inv(16) patients, as well as from the Kasumi-1 cell line and a U937 cell line expressing the AML1-ETO fusion gene. To assess the influence of associated epigenetic lesions, we performed gene expression studies in Kasumi-1 cells and cells extracted from an Inv(16) patient, both treated with demethylating and HDAC inhibitor agents. Shared deregulated genes in the different types of core-binding factor leukemias were identified. We found a tight link between Inv(16) and mutant AML1 samples. Furthermore, some of the genes deregulated by the leukemogenic process reverted to their normal expression with demethylating and HDAC inhibitor treatment, highlighting the role of chromatin remodeling processes in AML.

References

Sep 2, 1998·Proceedings of the National Academy of Sciences of the United States of America·J WangJ M Liu
Nov 20, 1998·Molecular and Cellular Biology·B LutterbachS W Hiebert
Jul 21, 2001·Molecular and Cellular Biology·S A BurelD E Zhang
Nov 20, 2001·Nucleic Acids Research·K L SugarsD S Latchman
Mar 29, 2002·Genes, Chromosomes & Cancer·Stephen E LangabeerDavid C Linch
Jan 2, 2003·Molecular and Cellular Biology·Kristie L DurstScott W Hiebert
Dec 9, 2003·The Journal of Clinical Investigation·Myriam AlcalayPier Giuseppe Pelicci
Feb 6, 2004·Journal of Biochemistry and Molecular Biology·Chunming Ding, Charles R Cantor
Apr 16, 2004·The New England Journal of Medicine·Lars BullingerJonathan R Pollack
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Apr 20, 2004·PLoS Biology·Eric Bair, Robert Tibshirani
May 25, 2004·Oncogene·Luke F Peterson, Dong-Er Zhang
May 25, 2004·Oncogene·Katsuya ShigesadaP Paul Liu
Jan 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yue-Ying WangSai-Juan Chen
Feb 3, 2005·Oncogene·Lindsay C SpenderPaul J Farrell
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey R InfanteMichael Goggins

❮ Previous
Next ❯

Citations

May 19, 2005·Cancer Genetics and Cytogenetics·Sükrü OztürkReyhan Diz Küçükkaya
Dec 20, 2000·Cancer Genetics and Cytogenetics·S OztürkY Perkçelen
Jun 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven M KornblauAlessandra Cesano
Aug 14, 2012·Advances in Biological Regulation·Sayyed K ZaidiGary S Stein
Jul 16, 2011·American Journal of Clinical Pathology·Lucia R WolgastHoward Ratech
Mar 12, 2010·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ciro MercurioPier Giuseppe Pelicci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.